Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04678193 · ClinicalTrials.gov registry record
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy
A clinical trial of COVID-19, sponsored by Aventyn.
- Recruiting
- Registry status
- 27,000
- Enrollment target
- 3
- Study locations
NCT04678193: Recruiting study of COVID-19, sponsored by Aventyn.
NCT04678193 is a study of COVID-19 that is actively recruiting participants, run by Aventyn. The registered enrollment target is 27,000 participants, below the 38,374-participant average among 298 other COVID-19 trials with a reported enrollment target (30% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04678193, a study of COVID-19, is actively recruiting participants, sponsored by Aventyn.
- RECRUITING
- Registry status
- 27,000 participants
- Enrollment target
- 3
- Study locations
Study Summary
Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to study in Phase 1, epidemiological variations in COVID-19 presentation in both PCR positive and negative subjects in the registry. Assessment of variables, predictive modeling of variables that impact severity of COVID-19 positive and negative subjects and assessment of predictors for post COVID-19 complications. In Phase 2, 2700 subjects with COVID-19 positive test will be studied in the intervention group comparing ECL-19 vs placebo with primary end point of hospital admission assessment. Treatment strategy for PCR positive COVID-19 subjects in the registry who are in Stage I of the disease process with ECL-19 drug compared to placebo in reducing hospital admissions
Conditions Studied
Interventions
- DRUG Coromec Registry with ECL-19
Study Locations (3)
Other
- Multiple Locations - Bangalore
- Multiple Locations - Stockholm
Arizona
- Multiple Locations - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27,000 participants |
| Start Date | 2020-12-24 |
| Est. Completion | 2026-06-30 |
What NCT04678193 shows while recruiting
NCT04678193 is an observational study that tracks outcomes without assigning an intervention. Its 27,000 participants enrollment target places it among the larger protocols in the corpus, below the 38,374-participant average among 298 other COVID-19 trials with a reported enrollment target (30% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Coromec Registry with ECL-19 is the first listed.
NCT04678193 reports a single indexed study location in Other, Arizona.
Frequently Asked Questions
What is clinical trial NCT04678193 about?
NCT04678193 is a clinical study titled "COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy". Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to stud...
What is the current status of trial NCT04678193?
This trial is currently recruiting. The enrollment target is 27,000 participants. The study started on 2020-12-24. Estimated completion is 2026-06-30.
What conditions does trial NCT04678193 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04678193?
The interventions under investigation include: Coromec Registry with ECL-19 (DRUG).
Who is sponsoring clinical trial NCT04678193?
This trial is sponsored by Aventyn, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04678193 being conducted?
This trial has 3 study locations across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04678193's enrollment target sits among peer trials
27,000 13th of 298 higher than 286 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04494945 · 27,500 participants · NA
Identifying and Caring for Individuals With Inherited Cancer Syndrome
- NCT03175302 · 25,240 participants
PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI